Company intelligence / Profile preview

GAIA

Ownership: Public · GAIA
Employees: ~250
Development stage: Other

Overview

GAIA’s DTx products have demonstrated effect sizes and safety profiles comparable to modern medications for mental health conditions. Their flagship product "deprexis" has shown efficacy similar to antidepressants across at least fifteen RCTs. Other programs have published results in leading journals such as The Lancet Digital Health.

Therapeutic areas: OncologyEndocrinologyPsychiatryDermatologyCardiovascularNeurologyInfectious Diseases
Modalities: Non-pharmacological therapy (Digital therapeutics)Artificial intelligence-powered digital therapy
Industry: Digital Health Medical Devices

Partnerships

Leading universities/corporate partners globallyAirbus (co-developer of broca platform)

Financials

Market cap: $32.5M
Total revenue: $99M
Enterprise value: $39.6M

Beyond the preview

Go deeper on GAIA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GAIA.